



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

Ref: PDL: AUGUST: 2018

Dated: 14.08.2018

The National Stock Exchange of India Limited
"Exchange Plaza", Banda Kurla Complex
Bandra East, Mumbai
Maharashtra

Listing Compliance Cell
BSE Limited
PhirozeJeejeebhoy Towers
Dalal Street, Mumbai


SUBJECT: SUBMISSION OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON
30th JUNE, 2018

Sir/Madam

Pursuant to Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the UN-Audited Financial Results of the Company for the Quarter ended on 30th June, 2018 as approved by the Board of Directors in its meeting held on Tuesday, the 14th day of August, 2018, along with the Report of Auditor.

You are requested to display the same on the Notice Board of your Exchange for the information of members and general public.

For & On Behalf of Parabolic Drugs Limited

Sincerely
For Parabolic Drugs Ltd

Authorised Signatory
Authorised Signatory

V.K. JINDAL & ASSOCIATES
CHARTERED ACCOUNTANTS

PLOT NO. 5, SECTOR-1
INDUSTRIAL AREA,
PARWANOO.
PH. 01792-233229.
MOB. NO. 08699229555

**Independent Auditor's Review Report on Standalone Quarterly Financial
Results of the Company pursuant to the Regulation 33 of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations,2015**

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of **M/s Parabolic Drugs Limited ("the Company")** having **Registered Office at SCO 186-187, Second Floor, Sector-8C, Chandigarh** for the **Quarter ended 30th June, 2018** being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the entity*, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


Based on our review conducted as above and **subject to Annexure-'A'**, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable Indian accounting standards (Ind AS) specified under section 133 of the Companies Act, 2013 and SEBI Circulars CIR/CFD/CMD/15/2015 dated 30 November 2015 and CIR/CFD/FAC/62/2016 dated 5 July 2016 , and other recognized accounting practices and policies has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Chandigarh;

Dated: 14th August,2018

FOR V K JINDAL & ASSOCIATES,

CHARTERED ACCOUNTANTS



FRN No.006244N

(Vijay Jindal)

Partner

Membership No: 084128

Name: M/s. V K Jindal & Associates.
Chartered Accountants
Address: Plot No 5, Sector- 1,
Industrial Area, Parwanoo

Annexure -'A'


Notes on the Un audited financial results of M/s Parabolic Drugs Limited
For the Quarter ended 30th June,2018

1. Debit or Credit Balances on whatever account are subject to confirmation.
2. Depreciation has been provided for on pro-rata basis as per Companies Act, 2013.
3. Figures of the previous year/Quarter have been rearranged/regrouped wherever considered necessary.

Chandigarh;

Dated: 14th August,2018

FOR V K JINDAL & ASSOCIATES.,
CHARTERED ACCOUNTANTS


FRN No. 005244N
(Vijay Jindal)
Partner
Membership No: 084128

Name: M/s. V K Jindal & Associates.
Chartered Accountants
Address: Plot No 5, Sector- 1,
Industrial Area, Parwanoo




PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

Registered Office: SCO. 186-187, Second Floor, Sector - 8C, Chandigarh
Statement ~~UNA~~Audited Financial Results for the Quarter ended 30th June 2018

Sr. No.	Particulars	Quarter ended			Rs. In crores
		30.06.2018	31.03.2018	30.06.2017	Year Ended
		Unaudited	Unaudited	Unaudited	31.03.2018 Audited
I	Revenue from Operations				
	(a) Net Sales (Net of Excise duty)	12.85	16.23	15.33	71.79
	(b) Other Operating Income	0.00	0.00	0.70	0.81
	Total Revenue from Operations (Net of Excise Duty)	12.85	16.23	16.03	72.60
II	Other Income	0.13	0.02	3.78	4.11
III	Total Income (I + II)	12.98	16.25	19.81	76.71
IV	Expenses:				
	(a) Cost of materials consumed	10.31	16.14	14.02	64.22
	(b) Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods work-in-progress and Stock-in-Trade	1.20	(2.02)	(0.03)	(0.73)
	(d) Employees benefits expense	1.13	1.49	2.37	8.88
	(e) Finance Cost	1.26	2.09	2.56	8.35
	(f) Depreciation and amortization expense	5.73	8.59	8.65	34.54
	(g) Other expenses	5.06	3.76	4.41	16.27
	Total expenses (IV)	24.70	30.05	31.97	131.53
V	Profit / (Loss) before exceptional and extraordinary items and tax (III-IV)	(11.72)	(13.80)	(12.16)	(54.82)
VI	Exceptional Items	0.00	0.00	0.00	0.00
VII	Profit / (Loss) before extraordinary items and tax (V - VI)	(11.72)	(13.80)	(12.16)	(54.82)
VIII	Tax expenses:				
	(a) Current tax	0.00	0.00	0.00	0.00
	(b) Deferred tax	(1.20)	0.47	0.45	1.76
IX	Net Profit / (Loss) after tax from Continuing Operations (VII-VIII)	(10.52)	(14.27)	(12.61)	(56.58)
X	Other Comprehensive Income / (Expense) (Net of Tax)	0.00	(0.42)	0.00	(0.42)
XI	Total Comprehensive Income / (Expense) (Net of Tax)	(10.52)	(14.69)	(12.61)	(57.00)
XII	Paid-up Equity share capital (Face value of Rs.10/- each)				
	- Issued and Subscribed Capital	61.89	61.89	61.89	61.89
XIII	Earning Per Share (EPS) (Equity shares of Rs. 10/- each fully paid up)				
	a) Basic in Rs.	(1.70)	(2.37)	(2.04)	(9.21)
	b) Diluted in Rs.	(1.70)	(2.37)	(2.04)	(9.21)



Works : Village Sundhyan, P.O. Mubarakpur, Derabassi,
Distt. Mohali, Punjab, India. Tel: +91-1762-308657
Website: www.parabolicdrugs.com



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

Notes :

1. The above quarterly results have been reviewed & recommended by the Audit Committee and taken on record by the Board of Directors in their meeting held on 14th August 2018 and the same have been reviewed by the Statutory Auditors.
2. During the period under review, the company has incurred loss owing to the unfavorable market conditions, interest burden and economic stress, the company has witnessed an erosion in the margins of key products.
3. The promoters' shareholding (22619927 Equity shares) has been pledged pursuant to the terms of CDR package.
4. There is not more than one reportable segment i.e. Pharmaceuticals business only hence information as per AS17 is not required to be disclosed.
5. The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
6. During the quarter ended 30th June 2018, most of Banks have not charged interest due to NPA Status of Loan Accounts. Hence no Provision for interest amounting to Rs 34.69 crore for the quarter ended 30th June 2018 on these loans has been made, on the belief that such interest would be waived at the time of final settlement.
7. As per Ind. AS 18, Revenue for the quarter ended 30th June 2018 is reported net of duties.
8. M/s J.M. Financial Asset Reconstruction Company Private Limited has already taken over the Loans/Debts of ICICI, UCO, IDBI & SBI. However the balance with M/s J M Financial Asset Reconstruction Company Private Limited is subject to confirmation & Reconciliation as on 30.6.2018
9. The balance in Loan accounts with SIDBI, Union Bank of India, EXIM Bank and Central Bank of India Cash Credit Account is subject to confirmation & Reconciliation as on 30.6.2018
10. During the quarter ended 30.06.2018, M/s J.M. Financial Asset Reconstruction Company Private Limited has sold the company's manufacturing unit situated at Panchkula by enforcing security interest under SARFAESI Act, 2002.
11. Finance cost includes price difference of Raw Material charged by the supplier.
12. Tax Expenses includes Income Tax & deferred Tax liability (Net).

Place : Chandigarh
Date : 14th August 2018

For Parabolic Drugs Limited

Pranav Gupta
Managing Director

